News
Keyword Search
| Date | Title | Teaser | |
|---|---|---|---|
|
12/06/22
|
Summary ToggleIridex to Participate in Fireside Chat with Stifel Equity Research | MOUNTAIN VIEW, Calif. , Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat with its covering |
|
|
11/10/22
|
Summary ToggleIridex Announces Record Third Quarter 2022 Financial Results | Company Announces FDA Clearance of new Iridex Pascal® Scanning Laser Platform MOUNTAIN VIEW, Calif. , Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today |
|
|
10/27/22
|
Summary ToggleIridex to Report Third Quarter 2022 Financial Results on November 10, 2022 | MOUNTAIN VIEW, Calif. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2022 |
|
|
09/29/22
|
Summary ToggleIridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022 | MicroPulse ® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways to manage, preserve, and prolong vision for glaucoma patients. |
|
|
08/18/22
|
Summary ToggleIridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase | MOUNTAIN VIEW, Calif. , Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the company will present at the upcoming Inaugural Gilmartin Group |
|
|
08/15/22
|
Summary ToggleIridex Announces Second Quarter 2022 Financial Results | MOUNTAIN VIEW, Calif. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022 . Second Quarter 2022 Highlights Total revenue of $13.8 million , an increase of 2% over the prior year period Gross Margin was |
|
|
08/01/22
|
Summary ToggleIridex to Report Second Quarter 2022 Financial Results on August 15, 2022 | MOUNTAIN VIEW, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2022 |
|
|
06/14/22
|
Summary ToggleIridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China | MOUNTAIN VIEW, Calif. , June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6 |
|
|
05/12/22
|
Summary ToggleIridex Announces First Quarter 2022 Financial Results | Achieved Record First Quarter Revenue MOUNTAIN VIEW, Calif. , May 12, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022 . First Quarter 2022 Highlights Record first quarter revenue of $13.4 million , an increase of |
|
|
04/28/22
|
Summary ToggleIridex to Report First Quarter 2022 Financial Results on May 12, 2022 | MOUNTAIN VIEW, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of |
|
|
03/21/22
|
Summary ToggleIridex Announces the Appointment of Beverly Huss to its Board of Directors | MOUNTAIN VIEW, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, |
|
|
03/10/22
|
Summary ToggleIridex Announces Fourth Quarter and Full Year 2021 Financial Results | Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 1, 2022 . |
|
|
03/08/22
|
Summary ToggleIridex to Present at the 34th Annual Roth Conference | MOUNTAIN VIEW, Calif. , March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34 th Annual Roth |
|
|
02/24/22
|
Summary ToggleIridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 | MOUNTAIN VIEW, Calif. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and |
|
|
01/11/22
|
Summary ToggleIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021 | Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , Jan. 11, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended |
|
